Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
-0.03 (-0.76%)
Oct 13 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 3.92 - 3.92
52 week 2.75 - 7.00
Open 3.92
Vol / Avg. 600.00/2,698.00
Mkt cap 125.85M
P/E     -
Div/yield     -
EPS -0.68
Shares 32.29M
Beta 2.90
Inst. own     -
Nov 10, 2015
Q3 2015 Aurinia Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
Aurinia Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2015
Aurinia Pharmaceuticals Inc at Canaccord Genuity Growth Conference
Aug 11, 2015
Q2 2015 Aurinia Pharmaceuticals Inc Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1242.37% -5988.13%
Operating margin -10257.63% -6600.72%
EBITD margin - -5669.42%
Return on average assets -6.36% -44.07%
Return on average equity -10.58% -70.56%
Employees 26 -
CDP Score - -


1203-4464 Markham St
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links


Aurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis (LN). LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease, the requirement for life-long dialysis, or death. The Company had completed two Phase III studies of voclosporin in patients with moderate to severe psoriasis. The Company had completed a Phase IIb clinical trial of voclosporin in de novo renal transplant recipients. The Company's wholly owned subsidiaries include Aurinia Pharmaceuticals, Inc. and Aurinia Pharma Limited.

Officers and directors

Richard M. Glickman L.L.D Executive Chairman of the Board
Age: 57
Stephen W. Zaruby President, Chief Executive Officer, Director
Age: 51
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
Benjamin Rovinski Ph.D. Independent Director
Age: 58
Charles A. Rowland Jr. Independent Director
Age: 56